Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with ...

PD-L1 is a cell surface receptor expressed on both tumour and regulatory ... given as a monotherapy or in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab), a widely-used treatment ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% ...

Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment ...

Study findings suggest the potential to repurpose a drug that is FDA-approved for treating asthma and eczema, to enhance ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...